CAR-T

Novartis’ CAR-T cancer drug available on NHS to young people
Novartis’ CAR-T cancer drug available on NHS to young people
Pharmaforum
Novartis
CAR-T
NHS
refractory B-cell acute lymphoblastic leukemia
Kymriah
Flag link:
June highlights shorter CAR T culture times at SITC
June highlights shorter CAR T culture times at SITC
BioCentury
CAR-T
SITC
Flag link:
Waiting for bluebird bio to Sing at ASH
Waiting for bluebird bio to Sing at ASH
Motley Fool
Bluebird Bio
earnings
ASH
CAR-T
Flag link:
Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T
Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T
Endpoints
CAR-T
Xyphos Biosciences
Flag link:
NHS, Gilead reach agreement for Yescarta
NHS, Gilead reach agreement for Yescarta
BioCentury
Yescarta
Gilead Sciences
UK
NHS
CAR-T
Flag link:
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Biopharma Reporter
Novartis
Kymriah
competition
drug marketing
CAR-T
Flag link:
Allogene IPO could be year's largest biotech listing on NASDAQ
Allogene IPO could be year's largest biotech listing on NASDAQ
BioCentury
IPOs
NASDAQ
Allogene
CAR-T
Flag link:
Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects
Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects
Endpoints
Loyola University
CAR-T
drug development
Flag link:
NICE rejects Novartis’ CAR-T in adult lymphoma
NICE rejects Novartis’ CAR-T in adult lymphoma
Pharmaforum
NICE
UK
Novartis
CAR-T
Kymriah
NHS
diffuse large B-cell lymphoma
Flag link:
Allogene Therapeutics Announces Filing For IPO
Allogene Therapeutics Announces Filing For IPO
CP Wire
Allogene
IPOs
CAR-T
Flag link:
Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration
Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration
Endpoints
Atara
CAR-T
cancer
Flag link:
Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US
Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US
Biopharma Dive
Novartis
Kymriah
CAR-T
UK
Flag link:
Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths
Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths
Fierce Pharma
Juno Therapeutics
JCAR015
CAR-T
Flag link:
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
Reuters
Yescarta
UK
Europe
CAR-T
NICE
Gilead Sciences
Flag link:
Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe
Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe
Endpoints
Novartis
CAR-T
Kymriah
drug manufacturing
Flag link:
Does CAR-T Therapy Have a Payment Problem?
Does CAR-T Therapy Have a Payment Problem?
BioSpace
CAR-T
oncology
payers
Flag link:
After a hiring blitz, where is Mustang's CAR-T manufacturing headed?
After a hiring blitz, where is Mustang's CAR-T manufacturing headed?
Biopharma Dive
Mustang Bio
CAR-T
Flag link:
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Forbes
Regeneron
Bluebird Bio
CAR-T
drug discovery
gene therapy
cancer
Flag link:
Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy
Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy
Xtalks
Novartis
Kymriah
drug manufacturing
CAR-T
Cell for Cure
Flag link:
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Fierce Biotech
Celgene
clinical trials
bb2121
Bluebird Bio
Multiple Myeloma
CAR-T
Flag link:

Pages